Image deconvolution is often modeled as an optimization problem for a cost function involving two or more terms that represent the data fidelity and the image domain constraints (or penalties). While a number of choices for modeling the cost function and implementing the optimization algorithms exist, selection of the regularization parameter in the cost function usually involves empirical tuning, which is a tedious process. Any optimization framework provides a family of solutions, depending on the numerical value of the regularization parameter. The end-user has to perform the task of tuning the regularization parameter based on visual inspection of the recovered solutions and then use the suitable image for further applications. In this work, we present an image deconvolution framework using the methodology of mean gradient descent (MGD), which does not involve any regularization parameter. The aim of our approach is instead to arrive at a solution point where the different costs balance each other. This is achieved by progressing the solution in the direction that bisects the steepest descent directions corresponding to the two cost terms in each iteration. The methodology is illustrated with numerical simulations as well as with experimental image records from a bright-field microscope system and shows uniform deconvolution performance for data with different noise levels. MGD offers an efficient and user-friendly method that may be employed for a variety of image deconvolution tools. The MGD approach as discussed here may find applications in the context of more general optimization problems as well.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1364/AO.426353 | DOI Listing |
High-resolution non-line-of-sight (NLOS) imaging under nanosecond time-resolution conditions is challenging in applications. We propose a novel NLOS imaging method consisting of deconvolution modified iterative back projection and virtual modulated range migration for low time-resolution system, obtaining super-resolution (SR) histogram signal and high-resolution NLOS images sequentially. The proposed method is applicable to both confocal and non-confocal configurations.
View Article and Find Full Text PDFHum Brain Mapp
January 2025
Center for MR Research, University Children's Hospital Zurich, Zurich, Switzerland.
The human brain connectome is characterized by the duality of highly modular structure and efficient integration, supporting information processing. Newborns with congenital heart disease (CHD), prematurity, or spina bifida aperta (SBA) constitute a population at risk for altered brain development and developmental delay (DD). We hypothesize that, independent of etiology, alterations of connectomic organization reflect neural circuitry impairments in cognitive DD.
View Article and Find Full Text PDFJ Immunother Cancer
January 2025
Providence Portland Medical Center, Portland, Oregon, USA.
Objectives: Multiplex immunohistochemistry and immunofluorescence (mIHC/IF) are emerging technologies that can be used to help define complex immunophenotypes in tissue, quantify immune cell subsets, and assess the spatial arrangement of marker expression. mIHC/IF assays require concerted efforts to optimize and validate the multiplex staining protocols prior to their application on slides. The best practice guidelines for staining and validation of mIHC/IF assays across platforms were previously published by this task force.
View Article and Find Full Text PDFNeuro Oncol
January 2025
MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.
Background: Meningiomas exhibit considerable clinical and biological heterogeneity. We previously identified four distinct molecular groups (immunogenic, NF2-wildtype, hypermetabolic, proliferative) that address much of this heterogeneity. Despite the utility of these groups, the stochasticity of clustering methods and the use of multi-omics data for discovery limits the potential for classifying prospective cases.
View Article and Find Full Text PDFBiol Pharm Bull
January 2025
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.
As unexpected adverse events and successful drug repositioning have shown, drug effects are complex and include aspects not recognized by developers. How can we understand these unrecognized drug effects? Drug effects can be numerized by encompassing biological responses to drugs. For instance, the transcriptome data of cultured cells and toxicopathological images of mice treated with a compound represent the effects of the compound in vitro and in vivo, respectively.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!